Key result
Premedication with acetyl salicylic acid and phthalazinol prevented persistent cerebral smooth muscle contraction in response to whole blood in an in vitro model.
Why the study?
Does premedication with ASA and phthalazinol prevent persistent cerebral smooth muscle contraction in response to whole blood in an in vitro system?
Does premedication with ASA and phthalazinol prevent persistent cerebral smooth muscle contraction in response to whole blood in an in vitro system?
Premedication with platelet inhibitors ASA and phthalazinol prevents persistent cerebral smooth muscle contraction in response to whole blood in vitro, suggesting platelet aggregation chemicals play a role in vasospasm.
Should not change clinical practice; leaves open whether platelet inhibition prevents vasospasm in vivo.
Using an in vitro system designed to measure arterial constriction, we have demonstrated the importance of platelet function in maintaining cerebral smooth muscle contraction after whole blood injection. We tested two agents, acetyl salicylic acid (ASA) and phthalazinol, both known to interfere with platelet function. In control tests normal rabbit and monkey blood produced a reliable and persistent arterial constriction. In experimental tests blood drawn from animals premedicated with ASA and phthalazinol failed to produce a persistent contraction. These results support the hypothesis that chemicals released during platelet aggregation may be important in persistent vasospasm.
No takes yet. Share an insight, caveat, or question.
Linder et al. (1978) studied Cerebral vasospasm. Acetyl salicylic acid (ASA) and phthalazinol vs. Normal blood (control) was evaluated on Persistent arterial constriction. Premedication with acetyl salicylic acid and phthalazinol prevented persistent cerebral smooth muscle contraction in response to whole blood in an in vitro model.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: